Abstract:The use of propranolol for the treatment of infantile hemangioma (IH) has been widely investigated in recent years. However, the underlying therapeutic mechanism of propranolol for the treatment of IH remains poorly understood. The aim of the present study was to investigate the expression of proteins regulated by cellular tumor antigen p53 (p53) in associated apoptosis pathways in IH endothelial cells (HemECs) treated with propranolol. Furthermore, the present study aimed to investigate the exact apoptotic pathway underlying the therapeutic effect of propranolol against IH. In the present study, HemECs were subcultured and investigated using an inverted phase contrast microscope, immunocytochemical staining and a scanning electron microscope (SEM). Experimental groups and blank control groups were prepared. All groups were subjected to drug treatment. A high p53 expression model of HemECs was successfully established via transfection, and a low p53 expression model of HemECs was established using pifithrin-α. The apoptosis rate of each group was determined using Annexin V-fluorescein isothiocyanate/propidium iodide double staining and flow cytometry. The expression levels of downstream proteins regulated by p53 [tumour necrosis factor receptor superfamily member 6 (FAS), p53-induced death domain-containing protein (PIDD), death receptor 5 (DR5), BH3-interacting domain death agonist (BID), apoptosis regulator BAX (BAX), p53 unregulated modulator of apoptosis (PUMA), phosphatidylinositol-glycan biosynthesis class S protein (PIGS), and insulin-like growth factor-binding protein 3 (IGF-BP3)] were revealed in the experimental and control groups via western blotting. Microscopic observation revealed the growth of an adherent monolayer of cells, which were closely packed and exhibited contact inhibition. Immunocytochemical staining demonstrated increased expression of clotting factor VIII. SEM analysis revealed presence of Weibel-Palade bodies. The results of the analyses verified that the cultured cells were HemECs. The staining of the samples resulted in a significantly increased rate of apoptosis in experimental groups compared with the blank control group. This result suggested that there is an association between p53 expression and the rate of apoptosis of propranolol-treated HemECs. The results of the western blot analysis demonstrated an upregulation of BAX expression and a downregulation of IGF-BP3 expression in the HemECs treated with propranolol. There were no significant differences in the expression levels of FAS, DR5, PIDD, BID, PUMA and PIGS between experimental and control groups. This result suggests that p53 has an important role in HemEC apoptosis. The results of the present study additionally suggest that the propranolol-induced HemEC apoptosis pathway is a mitochondrial apoptosis pathway and is regulated by p53-BAX signaling.

Propranolol Induces Regression of Hemangioma Cells Via the Down-Regulation of the Pi3k/Akt/Enos/Vegf Pathway

Propranolol represses infantile hemangioma cell growth through the β2-adrenergic receptor in a HIF-1α-dependent manner.

Propranolol Inhibits Angiogenesis Via Down-Regulating the Expression of Vascular Endothelial Growth Factor in Hemangioma Derived Stem Cell

Propranolol Inhibits Endothelial Progenitor Cell Homing: a Possible Treatment Mechanism of Infantile Hemangioma.

Induction of apoptosis in infantile hemangioma endothelial cells by propranolol.

Propranolol inhibits stemness of hemangioma through Jagged1

Mechanisms of propranolol action in infantile hemangioma

Efficacy and adverse effects of oral propranolol in infantile hemangioma: a meta-analysis of comparative studies

Downregulation of Mir-382 by Propranolol Inhibits the Progression of Infantile Hemangioma Via the PTEN-mediated AKT/mTOR Pathway.

Propranolol Therapy for Infantile Hemangioma: Our Experience

Pigment Epithelium-Derived Factor/vascular Endothelial Growth Factor Ratio Plays a Crucial Role in the Spontaneous Regression of Infant Hemangioma and in the Therapeutic Effect of Propranolol.

Propranolol inhibits the angiogenic capacity of hemangioma endothelia via blocking β-adrenoceptor in mast cell

Propranolol Induces Hemangioma Endothelial Cell Apoptosis Via a P53-Bax Mediated Pathway

Clinical Efficacy and Therapeutic Mechanisms of Propranolol for Infancy Hemangiomas: an Update

Role of Thrombospondin-1 and Nuclear Factor-κB Signaling Pathways in Antiangiogenesis of Infantile Hemangioma

Research of the mechanisms of propranolol in the treatment of hemangiomas

The Use of Propranolol in the Treatment of Infantile Haemangiomas: an Update on Potential Mechanisms of Action

R(+) Propranolol decreases lipid accumulation in hemangioma-derived stem cells

The efficacy of oral propranolol for infantile hemangiomas in 68 cases

Combinative effects of β -elemene and propranolol on the proliferation, migration, and angiogenesis of hemangioma

Clinical efficacy of oral propranolol for the treatment of infant proliferating hemangiomas and the changes of serum VEGF